Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer

Gyeongsang National University Hospital

Status and phase: Completed; Phase 2

Conditions: Metastatic Pancreatic Cancer

Treatments: Drug: Gemcitabine, Cisplatin, Erlotinib (Tarceva)

Study type: Interventional

Funder types: Other

Identifiers

NCT00922896

Gyeongsang-001

Details and patient eligibility

About

The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.

Enrollment: 22 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age older than 18
• Younger than 75
• ECOG performance status 0 or 1
• Histologically confirmed adenocarcinoma of the pancreas
• Metastatic pancreatic cancer
• No prior chemotherapy for metastatic pancreatic cancer
• A patient with at least one measurable primary lesion of which the diameter is confirmed to be 10mm in Spiral CT or multidetector CT (MD CT)

Exclusion criteria

• A patient with no measurable disease
• A patient who received previous palliative chemotherapy for pancreatic cancer
• A patient with locally advanced pancreatic cancer
• A patient who received adjuvant chemotherapy for pancreatic cancer within 1 year
• A patient with previous active or passive immunotherapy
• A pregnant or lactating patient

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

22 participants in 1 patient group

GPE

Experimental group

Description:

Gemcitabine-Cisplatin-Erlotinib

Treatment:

Drug: Gemcitabine, Cisplatin, Erlotinib (Tarceva)